| Assay ID | Title | Year | Journal | Article |
|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1142172 | Metabolic stability in human liver microsomes assessed as compound remaining at 10 uM after 60 mins | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1151394 | Selectivity ratio of IC50 for 5-HT2B receptor (unknown origin) to Kb for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151379 | Antagonist activity at EP3 receptor (unknown origin) by functional cAMP assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1528795 | Antagonist activity at human EP2 transfected in rat C6 cells assessed as decrease in intracellular cAMP incubated for 10 mins followed by PGE2 addition and measured after 40 mins by TR-FRET assay | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models. |
| AID1142171 | Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 60 mins | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1551729 | Selectivity index, ratio of kb for EP4 receptor (unknown origin) to kb for human EP2 receptor | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives. |
| AID1142169 | Cytotoxicity against rat C6 cells assessed as cell viability | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1151365 | Inhibition of status epilepticus mouse assessed as assessed as blockade of neuronal damage in hippocampus hilus region | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151377 | Antagonist activity at EP2 receptor (unknown origin) by functional cAMP assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151382 | Antagonist activity at prostanoid IP receptor (unknown origin) by functional cAMP assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151387 | Selectivity ratio of Kb for prostanoid IP receptor (unknown origin) to Kb for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151393 | Inhibition of 5-HT2B receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1142165 | Antagonist activity at human EP4 receptor expressed in rat C6 cells assessed as intracellular cAMP accumulation treated for 10 mins prior to PGE2 challenge for 40 mins by TR-FRET assay | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142166 | Antagonist activity at human IP receptor expressed in rat C6 cells assessed as intracellular cAMP accumulation treated for 10 mins prior to iloprost challenge for 40 mins by TR-FRET assay | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142164 | Aqueous solubility of the compound in PBS buffer with 1% DMSO at pH 7.4 by nephelometry | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142163 | Selectivity index, ratio of KB for human DP1 receptor expressed in rat C6 cells to KB for human EP2 receptor expressed in rat C6 cells | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1151380 | Antagonist activity at EP4 receptor (unknown origin) by functional cAMP assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1156007 | Competitive antagonist activity at human EP2 receptor assessed as inhibition of PGE2-induced response | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | Development of second generation EP2 antagonists with high selectivity. |
| AID1142177 | Cmax in C57BL/6 mouse at 3 mg/kg, iv | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142168 | Selectivity index, ratio of KB for human IP receptor expressed in rat C6 cells to KB for human EP2 receptor expressed in rat C6 cells | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142189 | Ratio of drug level in brain to plasma in C57BL/6 mouse at 3 mg/kg, iv measured after 1 to 2 hrs | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1151381 | Antagonist activity at DP1 receptor (unknown origin) by functional cAMP assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151378 | Antagonist activity at EP1 receptor (unknown origin) by functional cAMP assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151385 | Selectivity ratio of Kb for EP3 receptor (unknown origin) to Kb for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1551728 | Competitive inhibition of EP4 receptor (unknown origin) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives. |
| AID1142162 | Antagonist activity at human DP1 receptor expressed in rat C6 cells assessed as intracellular cAMP accumulation at 10 uM treated for 10 mins prior to BW245C challenge for 40 mins by TR-FRET assay | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142174 | Metabolic stability in mouse liver microsomes assessed as compound remaining at 10 uM after 60 mins | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1151388 | Selectivity ratio of Kb for DP1 receptor (unknown origin) to Kb for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151384 | Selectivity ratio of Kb for EP1 receptor (unknown origin) to Kb for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1142185 | Terminal half life in C57BL/6 mouse plasma at 3 mg/kg, iv | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1151383 | Inhibition of EP2 receptor (unknown origin) by competitive binding assay | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1551727 | Competitive inhibition of human EP2 receptor expressed in C6G cells preincubated for 5 mins followed by increase in PGE2 concentration measured after 40 mins by radioligand binding assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives. |
| AID1151367 | Inhibition of status epilepticus mouse assessed as assessed as blockade of neuronal damage in hippocampus CA1 region | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1151386 | Selectivity ratio of Kb for EP4 receptor (unknown origin) to Kb for EP2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1142161 | Antagonist activity at human EP2 receptor expressed in rat C6 cells assessed as 2-fold rightward shift in PGE2 concentration-response curve at 1 uM treated for 10 mins prior to PGE2 challenge for 40 mins by TR-FRET assay | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142181 | AUC(last) in C57BL/6 mouse at 3 mg/kg, iv | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142173 | Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 60 mins | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1151366 | Inhibition of status epilepticus mouse assessed as assessed as blockade of neuronal damage in hippocampus CA3 region | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
| Prostanoid receptor EP2 as a therapeutic target. |
| AID1142170 | Therapeutic index, ratio of CC50 for rat C6 cells to KB for human EP2 receptor expressed in rat C6 cells | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1142167 | Selectivity index, ratio of KB for human EP4 receptor expressed in rat C6 cells to KB for human EP2 receptor expressed in rat C6 cells | 2014 | Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
| Lead optimization studies of cinnamic amide EP2 antagonists. |
| AID1346308 | Human EP2 receptor (Prostanoid receptors) | 2012 | Proceedings of the National Academy of Sciences of the United States of America, Feb-21, Volume: 109, Issue:8
| Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |